CXCL13 as a novel marker for diagnosis and disease monitoring in pediatric PTLD

American Journal of Transplantation

Volumn 12, Issue 6, 2012, Pages 1610-1617

  Schiffer, L ^a,b   Henke Gendo, C ^a   Wilsdorf, N ^a,b   Hussein, K ^a   Pape, L ^a,b   Schmitt, C ^a   Haller, H ^a   Schiffer, M ^a   Klein, C ^a,c   Kreipe, H ^a   Maecker Kolhoff, B ^a,b  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b Integrated Research and Treatment Center Transplantation (IFB Tx)   (Germany)

^c LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

CXCL13; pediatric; posttransplant lymphoproliferative disease; PTLD; solid organ transplantation

Indexed keywords

BIOLOGICAL MARKER; CXCL13 CHEMOKINE; CYTOTOXIC AGENT; RITUXIMAB; VIRUS DNA;

ADOLESCENT; ADULT; ARTICLE; B CELL LYMPHOMA; BURKITT LYMPHOMA; CANCER CHEMOTHERAPY; CHILD; CHILDHOOD DISEASE; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DENDRITIC CELL; DIAGNOSTIC VALUE; ENZYME LINKED IMMUNOSORBENT ASSAY; EPSTEIN BARR VIRUS INFECTION; FEMALE; GRAFT RECIPIENT; GROUPS BY AGE; HODGKIN DISEASE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; MALE; ORGAN TRANSPLANTATION; PATIENT MONITORING; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PREDICTIVE VALUE; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; REMISSION; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VIRUS LOAD; VIRUS REACTIVATION;

ADOLESCENT; BASE SEQUENCE; CHEMOKINE CXCL13; CHILD; CHILD, PRESCHOOL; DNA PRIMERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; LYMPHOPROLIFERATIVE DISORDERS; MALE; MONITORING, PHYSIOLOGIC;

EID: 84861825016     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03968.x     Document Type: Article

References (19)

1. Parker A, Bowles K, Bradley JA, et al,. Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines. Br J Haematol 2009; 149: 675-692.
2. Maecker B, Jack T, Zimmermann M, et al,. CNS or bone marrow involvement as risk factors for poor survival in post-transplantation lymphoproliferative disorders in children after solid organ transplantation. J Clin Oncol 2007; 25: 4902-4908.
3. Sebelin-Wulf K, Nguyen TD, Oertel S, et al,. Quantitative analysis of EBV-specific CD4/CD8 T cell numbers, absolute CD4/CD8 T cell numbers and EBV load in solid organ transplant recipients with PLTD. Transpl Immunol 2007; 17: 203-210.
4. Guppy AE, Rawlings E, Madrigal JA, Amlot PL, Barber LD,. A quantitative assay for Epstein-Barr virus-specific immunity shows interferon-gamma producing CD8+ T cells increase during immunosuppression reduction to treat posttransplant lymphoproliferative disease. Transplantation 2007; 84: 1534-1539.
5. Tosato G, Jones K, Breinig MK, McWilliams HP, McKnight JL,. Interleukin-6 production in posttransplant lymphoproliferative disease. J Clin Invest 1993; 91: 2806-2814.
6. Hinrichs C, Wendland S, Zimmermann H, et al,. IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: A longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transpl Int 2011; 24: 892-903.
7. Barton M, Wasfy S, Hebert D, et al,. Exploring beyond viral load testing for EBV lymphoproliferation: Role of serum IL-6 and IgE assays as adjunctive tests. Pediatr Transplant 2010; 14: 852-858.
8. Haque T, Chaggar T, Schafers J, Atkinson C, McAulay KA, Crawford DH,. Soluble CD30: A serum marker for Epstein-Barr virus-associated lymphoproliferative diseases. J Med Virol 2011; 83: 311-316.
9. Falkenhagen KM, Braziel RM, Fraunfelder FW, Smith JR,. B-Cells in ocular adnexal lymphoproliferative lesions express B-cell attracting chemokine 1 (CXCL13). Am J Ophthalmol 2005; 140: 335-337.
10. Smith JR, Braziel RM, Paoletti S, Lipp M, Uguccioni M, Rosenbaum JT,. Expression of B-cell-attracting chemokine 1 (CXCL13) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. Blood 2003; 101: 815-821.
11. Fischer L, Korfel A, Pfeiffer S, et al,. CXCL13 and CXCL12 in central nervous system lymphoma patients. Clin Cancer Res 2009; 15: 5968-5973.
12. Schiffer L, Kumpers P, Davalos-Misslitz AM, et al,. B-cell-attracting chemokine CXCL13 as a marker of disease activity and renal involvement in systemic lupus erythematosus (SLE). Nephrol Dial Transplant 2009; 24: 3708-3712.
13. Maecker B, Mougiakakos D, Zimmermann M, Behrens M, Hollander S, Schrauder A, et al,. Dendritic cell deficiencies in pediatric acute lymphoblastic leukemia patients. Leukemia 2006; 20: 645-649.
14. Engelmann I, Petzold DR, Kosinska A, Hepkema BG, Schulz TF, Heim A,. Rapid quantitative PCR assays for the simultaneous detection of herpes simplex virus, varicella zoster virus, cytomegalovirus, Epstein-Barr virus, and human herpesvirus 6 DNA in blood and other clinical specimens. J Med Virol 2008; 80: 467-477.
15. Schiffer L, Kielstein J, Haubitz M, et al,. Elevation of serum CXCL13 in SLE as well as in sepsis. Lupus 2011; 20: 507-511.
16. Sansonno D, Tucci FA, Troiani L, et al,. Increased serum levels of the chemokine CXCL13 and up-regulation of its gene expression are distinctive features of HCV-related cryoglobulinemia and correlate with active cutaneous vasculitis. Blood 2008; 112: 1620-1627.
17. Ehlin-Henriksson B, Liang W, Cagigi A, Mowafi F, Klein G, Nilsson A,. Changes in chemokines and chemokine receptor expression on tonsillar B cells upon Epstein-Barr virus infection. Immunology 2009; 127: 549-557.
18. Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA,. Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 2007; 110: 3316-3325.
19. Yu H, Shahsafaei A, Dorfman DM,. Germinal-center T-helper-cell markers PD-1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T-cell lymphoma. Am J Clin Pathol 2009; 131: 33-41.